US Stock MarketDetailed Quotes
REPL Replimune
- 14.930
- +3.880+35.11%
Close Nov 22 16:00 ET
- 14.830
- -0.100-0.67%
Post 19:58 ET
1.02BMarket Cap-4911P/E (TTM)
17.000High13.130Low6.07MVolume13.680Open11.050Pre Close94.00MTurnover13.91%Turnover RatioLossP/E (Static)68.42MShares17.00052wk High2.68P/B651.56MFloat Cap4.92052wk Low--Dividend TTM43.64MShs Float54.850Historical High--Div YieldTTM35.02%Amplitude4.920Historical Low15.490Avg Price1Lot Size
About Replimune Company
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Company Profile
SymbolREPL
Company NameReplimune
Listing DateJul 20, 2018
Issue Price15.00
Founded2017
CEODr. Sushil Patel, PhD
MarketNASDAQ
Employees331
Fiscal Year Ends03-31
Address500 Unicorn Park Drive,Suite 303,3rd Floor
CityWoburn
ProvinceMassachusetts
CountryUnited States of America
Zip Code01801
Phone1-781-222-9600
Websitehttp://www.replimune.com
Company Executives
- Name
- Position
- Salary
- Dr. Sushil Patel, PhD
- Director and Chief Executive Officer
- --
- Dr. Konstantinos Xynos, M.D.
- Chief Medical Officer
- 2.45M
- Andrew Schwendenman
- Chief Accounting Officer
- --
- Christopher Sarchi
- Chief Commercial Officer
- --
- Paul Bullock
- Chief Manufacturing Officer
- --
- Emily Hill
- Chief Financial Officer
- 3.38M
- Philip Astley-Sparke
- Executive Chairman of the Board
- 6.02M
- Veleka Peeples-Dyer
- Independent Director
- 667.97K
- Dr. Kapil Dhingra, M.B.B.S.
- Independent Director
- 357.60K
- Madhavan Balachandran
- Independent Director
- --
- Paolo Pucci
- Independent Director
- 360.10K
- Dieter Weinand
- Lead Independent Director
- 516.81K
- Christy J. Oliger
- Independent Director
- 352.60K
- Joseph P. Slattery, C.P.A.
- Independent Director
- 362.60K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
